{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-018664","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.982349+00:00","generated_at":"2026-06-19T18:19:40.240156+00:00","sec_items":["3.03","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Priveterra extends business combination deadline to Aug 11, 2023; ~$258.8M redeemed","bullets":["Shareholders approved extending the business combination deadline from Feb 11, 2023 to Aug 11, 2023.","Approval vote: 24,548,209 for, 3,245,246 against, with 2,463 abstentions.","Holders of 25,597,728 shares redeemed at ~$10.11/share for aggregate ~$258.8 million.","Redemption represents approximately 74% of total outstanding shares (based on 34.5M shares outstanding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-018664","json":"https://secwatch.observer/filing/0001104659-23-018664.json","markdown":"https://secwatch.observer/filing/0001104659-23-018664.md","text":"https://secwatch.observer/filing/0001104659-23-018664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923018664/0001104659-23-018664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923018664/tm236357d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T18:19:40.240156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"696e2c9ce6e5eedf4b1c54a40c6942787028b82f","claim":"AEON Biopharma, Inc.: Amended the contractual expiration date for completing a business combination from February 11, 2023 to August 11, 2023 (effective 2023-02-10).","evidence_excerpt":"the certificate of amendment to the second amended and restated certificate of incorporation (the “Charter Amendment”) to amend the Company’s contractual expiration date of February 11, 2023 by changing the date by which the Company must cease all operations except for the purpose of winding up if it fails to complete a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination (a “Business Combination”) from February 11, 2023 to August 11, 2023","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923018664/0001104659-23-018664-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-02-10"}],"fact_type":"governance_change"},{"claim_id":"a2e8bab2bd0ca1f9b2a6707c49ea4344e533ea33","claim":"AEON Biopharma, Inc. shareholders approved To amend the second amended and restated certificate of incorporation to extend the date by which the Company must consummate a business combination from February 11, 2023 to August 11, 2023. at the 2023-02-11 meeting.","evidence_excerpt":"Proposal No. 1 – The Extension Amendment – to amend the Company’s second amended and restated certificate of incorporation to extend the date by which the Company must consummate a business combination from February 11, 2023 (the date which is 24 months from the closing date of the Company’s initial public offering of shares of Class A common stock) to August 11, 2023 (the date which is 30 months from the closing date of the initial public offering). For Against Abstain 24,548,209 3,245,246 2,463","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923018664/0001104659-23-018664-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}